Apnimed
apnimed.com
Actively hiring
Prescription Drugs
Health Care
Respiratory & Sleep Devices
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Apnimed Swings To Q2 Profit, Eyes February 2027 FDA Decision On AD109 In Obstructive Sleep Apnea
Apnimed, Inc. (APMD), a late-stage clinical pharmaceutical company, announced its financial results for the second quarter ended June 30, 2026, swinging to net income from a net loss in the prior-year period.
Read more
Report
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (
Read more
Report
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (
Read more
Report
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (
Read more
Report
Apnimed Strengthens Leadership Team with Appointments of Industry Veterans Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of ...
Read more
Report
Apnimed To Present Additional Phase 3 Data for AD109, an Investigational Oral Pill for Obstructive Sleep Apnea, at CHEST 2025 Annual Meeting
- Topline results and additional data from the pivotal SynAIRgy and LunAIRo Phase 3 studies - the largest clinical program of an investigational medication for...
Read more
Report
Apnimed Announces Acceptance of Two Late-breaking Presentations and a Core Interactive Session at the CHEST Annual Meeting Highlighting New Positive AD109 Phase 3 Data and the Current Unmet Need in Obstructive Sleep Apnea
/PRNewswire/ -- Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drugs that address the root causes of...
Read more
Report
Apnimed, Inc.
The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Apnimed, Inc. reflects the research output of authors from Apnimed, Inc. who published articles in the 145 journals included in the Na
Read more
Report
People
Barry Wohl
Executive Officer
Dennis Molnar
Executive Officer
Lawrence Miller
Executive Officer, Director
Michael Rogers
Executive Officer
Ramzi Benamar
Executive Officer
Gerald Chan
Director
Ron Farquhar
Director
Joseph Avellone
Director
James Galeota
Director
Isaac Cheng
Director
Stefan Larson
Director
Chris Dimitropoulos
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge
United States
HQ
Apnimed
1000-5000 est. staff
39 John F. Kennedy St., 4th Floor, Cambridge, MA 02138
Financials
Total raised
$372.4M
Latest round
Venture - Series Unknown
Funding rounds
10
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $25M | Details |
| Venture - Series Unknown | 2025 | $35M | Details |
| Venture - Series Unknown | 2025 | $16.5M | Details |
| Venture - Series Unknown | 2022 | $79.7M | Details |
| Venture - Series Unknown | 2022 | $62.5M | Details |
| Venture - Series Unknown | 2022 | $62.5M | Details |
| Venture - Series Unknown | 2021 | $25M | Details |
| Venture - Series Unknown | 2020 | $15M | Details |
| Venture - Series Unknown | 2018 | $25.6M | Details |
| Venture - Series Unknown | 2018 | $25.6M | Details |